288 related articles for article (PubMed ID: 22402735)
1. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Devenny JJ; Godonis HE; Harvey SJ; Rooney S; Cullen MJ; Pelleymounter MA
Obesity (Silver Spring); 2012 Aug; 20(8):1645-52. PubMed ID: 22402735
[TBL] [Abstract][Full Text] [Related]
2. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
4. Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment.
Horie I; Abiru N; Hongo R; Nakamura T; Ito A; Haraguchi A; Natsuda S; Sagara I; Ando T; Kawakami A
Diabetes Res Clin Pract; 2018 Jan; 135():178-184. PubMed ID: 29162514
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
[TBL] [Abstract][Full Text] [Related]
6. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Tanday N; Irwin N; Flatt PR; Moffett RC
Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
[TBL] [Abstract][Full Text] [Related]
10. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats.
Jaikumkao K; Promsan S; Thongnak L; Swe MT; Tapanya M; Htun KT; Kothan S; Intachai N; Lungkaphin A
J Cell Physiol; 2021 Sep; 236(9):6424-6440. PubMed ID: 33559163
[TBL] [Abstract][Full Text] [Related]
12. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients.
Kosugi R; Nakatani E; Okamoto K; Aoshima S; Arai H; Inoue T
Endocr J; 2019 Aug; 66(8):677-682. PubMed ID: 31130574
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
Chen L; LaRocque LM; Efe O; Wang J; Sands JM; Klein JD
Am J Med Sci; 2016 Nov; 352(5):517-523. PubMed ID: 27865300
[TBL] [Abstract][Full Text] [Related]
15. Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression.
Li G; Zhang Y; Wilsey JT; Scarpace PJ
J Endocrinol; 2004 Jul; 182(1):123-32. PubMed ID: 15225137
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
17. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
18. Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
Reidelberger R; Haver A; Chelikani PK; Apenteng B; Perriotte-Olson C; Anders K; Steenson S; Blevins JE
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1576-85. PubMed ID: 22510712
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
J Endocrinol; 2020 May; 245(2):193-205. PubMed ID: 32092034
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
